• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

疟原虫肌浆/内质网 Ca2+-ATP 酶(PfATP6)基因在未接触过基于青蒿素联合疗法的地理分布广泛的寄生虫群体中自发突变。

Spontaneous mutations in the Plasmodium falciparum sarcoplasmic/ endoplasmic reticulum Ca2+-ATPase (PfATP6) gene among geographically widespread parasite populations unexposed to artemisinin-based combination therapies.

机构信息

Laboratory of Malariology, Research Institute for Microbial Diseases, Osaka University, Suita, Osaka, Japan.

出版信息

Antimicrob Agents Chemother. 2011 Jan;55(1):94-100. doi: 10.1128/AAC.01156-10. Epub 2010 Oct 18.

DOI:10.1128/AAC.01156-10
PMID:20956593
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3019649/
Abstract

Recent reports on the decline of the efficacy of artemisinin-based combination therapies (ACTs) indicate a serious threat to malaria control. The endoplasmic/sarcoplasmic reticulum Ca(2+)-ATPase ortholog of Plasmodium falciparum (PfSERCA) has been suggested to be the target of artemisinin and its derivatives. It is assumed that continuous artemisinin pressure will affect polymorphism of the PfSERCA gene (serca) if the protein is the target. Here, we investigated the polymorphism of serca in parasite populations unexposed to ACTs to obtain baseline information for the study of potential artemisinin-driven selection of resistant parasites. Analysis of 656 full-length sequences from 13 parasite populations in Africa, Asia, Oceania, and South America revealed 64 single nucleotide polymorphisms (SNPs), of which 43 were newly identified and 38 resulted in amino acid substitutions. No isolates showed L263E and S769N substitutions, which were reportedly associated with artemisinin resistance. Among the four continents, the number of SNPs was highest in Africa. In Africa, Asia, and Oceania, common SNPs, or those with a minor allele frequency of ≥0.05, were less prevalent, with most SNPs noted to be continent specific, whereas in South America, common SNPs were highly prevalent and often shared with those in Africa. Of 50 amino acid haplotypes observed, only one haplotype (3D7 sequence) was seen in all four continents (64%). Forty-eight haplotypes had frequencies of less than 5%, and 40 haplotypes were continent specific. The geographical difference in the diversity and distribution of serca SNPs and haplotypes lays the groundwork for assessing whether some artemisinin resistance-associated mutations and haplotypes are selected by ACTs.

摘要

最近有报道称,青蒿素类复方疗法(ACT)的疗效下降,这对疟疾控制构成了严重威胁。据认为,疟原虫的肌浆/内质网 Ca(2+)-ATP 酶同源物(PfSERCA)是青蒿素及其衍生物的作用靶点。如果该蛋白是作用靶点,那么持续的青蒿素压力预计会影响 PfSERCA 基因(serca)的多态性。在此,我们对未接触过 ACT 的寄生虫群体中的 serca 多态性进行了研究,以期获得有关潜在青蒿素驱动的耐药寄生虫选择的基线信息。对来自非洲、亚洲、大洋洲和南美洲的 13 个寄生虫群体的 656 条全长序列进行分析,发现了 64 个单核苷酸多态性(SNPs),其中 43 个是新鉴定的,38 个导致了氨基酸替换。没有分离株显示出与青蒿素耐药性相关的 L263E 和 S769N 替换。在这四个大陆中,非洲的 SNPs 数量最多。在非洲、亚洲和大洋洲,常见的 SNPs(即次要等位基因频率≥0.05 的 SNPs)较少,大多数 SNPs 是特定于某个大陆的,而在南美洲,常见的 SNPs 则非常普遍,且常与非洲的 SNPs 相同。在所观察到的 50 种氨基酸单倍型中,只有一种单倍型(3D7 序列)在四个大陆均可见(64%)。48 种单倍型的频率低于 5%,且 40 种单倍型是特定于某个大陆的。serca SNPs 和单倍型在地理上的多样性和分布差异为评估 ACT 是否选择了某些与青蒿素耐药相关的突变和单倍型奠定了基础。

相似文献

1
Spontaneous mutations in the Plasmodium falciparum sarcoplasmic/ endoplasmic reticulum Ca2+-ATPase (PfATP6) gene among geographically widespread parasite populations unexposed to artemisinin-based combination therapies.疟原虫肌浆/内质网 Ca2+-ATP 酶(PfATP6)基因在未接触过基于青蒿素联合疗法的地理分布广泛的寄生虫群体中自发突变。
Antimicrob Agents Chemother. 2011 Jan;55(1):94-100. doi: 10.1128/AAC.01156-10. Epub 2010 Oct 18.
2
Genetic diversity and lack of artemisinin selection signature on the Plasmodium falciparum ATP6 in the Greater Mekong Subregion.大湄公河次区域恶性疟原虫 ATP6 的遗传多样性和缺乏青蒿素选择特征。
PLoS One. 2013;8(3):e59192. doi: 10.1371/journal.pone.0059192. Epub 2013 Mar 26.
3
Geographic structuring of the Plasmodium falciparum sarco(endo)plasmic reticulum Ca2+ ATPase (PfSERCA) gene diversity.恶性疟原虫肌浆(内)质网 Ca2+-ATP 酶(PfSERCA)基因多样性的地理结构。
PLoS One. 2010 Feb 25;5(2):e9424. doi: 10.1371/journal.pone.0009424.
4
Investigations into the role of the Plasmodium falciparum SERCA (PfATP6) L263E mutation in artemisinin action and resistance.对恶性疟原虫 SERCA(PfATP6)L263E 突变在青蒿素作用和耐药性中的作用的研究。
Antimicrob Agents Chemother. 2010 Sep;54(9):3842-52. doi: 10.1128/AAC.00121-10. Epub 2010 Jun 21.
5
Characterization of the Plasmodium falciparum sarcoplasmic/endoplasmic reticulum Ca2+-ATPase gene in samples from Equatorial Guinea before implementation of artemisinin-based combination therapy.在实施基于青蒿素的联合疗法之前,从赤道几内亚的样本中鉴定恶性疟原虫肌浆/内质网 Ca2+-ATP 酶基因。
Am J Trop Med Hyg. 2013 Jan;88(1):43-47. doi: 10.4269/ajtmh.2012.12-0364. Epub 2012 Nov 26.
6
Molecular assessment of atpase6 mutations associated with artemisinin resistance among unexposed and exposed Plasmodium falciparum clinical isolates to artemisinin-based combination therapy.未暴露和暴露于基于青蒿素联合疗法的恶性疟原虫临床分离株中与青蒿素耐药相关的 atpase6 突变的分子评估。
Malar J. 2012 Nov 9;11:373. doi: 10.1186/1475-2875-11-373.
7
Geographic Plasmodium falciparum sarcoplasmic reticulum Ca2+ ATPase (PfSERCA) genotype diversity in India.印度地区恶性疟原虫肌浆网 Ca2+-ATP 酶(PfSERCA)基因型多样性。
Acta Trop. 2020 Feb;202:105095. doi: 10.1016/j.actatropica.2019.105095. Epub 2019 Jul 16.
8
Lack of association of the S769N mutation in Plasmodium falciparum SERCA (PfATP6) with resistance to artemisinins.无 PfATP6 上 S769N 突变与青蒿素类药物耐药性之间缺乏关联。
Antimicrob Agents Chemother. 2012 May;56(5):2546-52. doi: 10.1128/AAC.05943-11. Epub 2012 Feb 21.
9
Diversity of the sarco/endoplasmic reticulum Ca(2+)-ATPase orthologue of Plasmodium falciparum (PfATP6).恶性疟原虫肌浆网/内质网Ca(2+) -ATP酶同源物(PfATP6)的多样性
Infect Genet Evol. 2008 May;8(3):340-5. doi: 10.1016/j.meegid.2008.02.002. Epub 2008 Feb 15.
10
Polymorphisms of the artemisinin resistant marker (K13) in Plasmodium falciparum parasite populations of Grande Comore Island 10 years after artemisinin combination therapy.青蒿素联合疗法实施10年后,大科摩罗岛恶性疟原虫种群中青蒿素抗性标志物(K13)的多态性
Parasit Vectors. 2015 Dec 15;8:634. doi: 10.1186/s13071-015-1253-z.

引用本文的文献

1
Molecular markers of anti-malarial drug resistance in Central, West and East African children with severe malaria.中非、西非和东非重症疟疾儿童抗疟药物耐药性的分子标志物
Malar J. 2017 May 23;16(1):217. doi: 10.1186/s12936-017-1868-y.
2
Molecular surveillance of Plasmodium falciparum drug resistance in the Republic of Congo: four and nine years after the introduction of artemisinin-based combination therapy.刚果共和国恶性疟原虫耐药性的分子监测:采用青蒿素联合疗法四年及九年后
Malar J. 2017 Apr 19;16(1):155. doi: 10.1186/s12936-017-1816-x.
3
Evaluation of artemether-lumefantrine efficacy in the treatment of uncomplicated malaria and its association with pfmdr1, pfatpase6 and K13-propeller polymorphisms in Luanda, Angola.在安哥拉罗安达评估蒿甲醚-本芴醇治疗非复杂性疟疾的疗效及其与pfmdr1、pfatpase6和K13-螺旋桨基因多态性的关联。
Malar J. 2015 Dec 16;14:504. doi: 10.1186/s12936-015-1018-3.
4
Monitoring artemisinin resistance in Plasmodium falciparum: comparison of parasite clearance time by microscopy and real-time PCR and evaluation of mutations in Pfatpase6 gene in Odisha state of India.监测恶性疟原虫对青蒿素的耐药性:印度奥里萨邦通过显微镜检查和实时聚合酶链反应比较寄生虫清除时间并评估Pfatpase6基因中的突变
Parasitol Res. 2015 Sep;114(9):3487-96. doi: 10.1007/s00436-015-4577-x. Epub 2015 Jun 27.
5
Ecotope-based entomological surveillance and molecular xenomonitoring of multidrug resistant malaria parasites in anopheles vectors.按蚊媒介中基于生态位的抗多药疟原虫的昆虫学监测和分子异体监测
Interdiscip Perspect Infect Dis. 2014;2014:969531. doi: 10.1155/2014/969531. Epub 2014 Oct 1.
6
The interplay between drug resistance and fitness in malaria parasites.疟原虫的耐药性与适应性之间的相互作用。
Mol Microbiol. 2013 Sep;89(6):1025-38. doi: 10.1111/mmi.12349. Epub 2013 Aug 16.
7
Genetic diversity and lack of artemisinin selection signature on the Plasmodium falciparum ATP6 in the Greater Mekong Subregion.大湄公河次区域恶性疟原虫 ATP6 的遗传多样性和缺乏青蒿素选择特征。
PLoS One. 2013;8(3):e59192. doi: 10.1371/journal.pone.0059192. Epub 2013 Mar 26.
8
Characterization of the Plasmodium falciparum sarcoplasmic/endoplasmic reticulum Ca2+-ATPase gene in samples from Equatorial Guinea before implementation of artemisinin-based combination therapy.在实施基于青蒿素的联合疗法之前,从赤道几内亚的样本中鉴定恶性疟原虫肌浆/内质网 Ca2+-ATP 酶基因。
Am J Trop Med Hyg. 2013 Jan;88(1):43-47. doi: 10.4269/ajtmh.2012.12-0364. Epub 2012 Nov 26.
9
Molecular assessment of atpase6 mutations associated with artemisinin resistance among unexposed and exposed Plasmodium falciparum clinical isolates to artemisinin-based combination therapy.未暴露和暴露于基于青蒿素联合疗法的恶性疟原虫临床分离株中与青蒿素耐药相关的 atpase6 突变的分子评估。
Malar J. 2012 Nov 9;11:373. doi: 10.1186/1475-2875-11-373.
10
Mechanisms of in vitro resistance to dihydroartemisinin in Plasmodium falciparum.体外疟原虫对双氢青蒿素耐药机制的研究。
Mol Microbiol. 2012 Oct;86(1):111-28. doi: 10.1111/j.1365-2958.2012.08180.x. Epub 2012 Aug 6.

本文引用的文献

1
Plasmodium falciparum accompanied the human expansion out of Africa.恶性疟原虫伴随着人类走出非洲而扩散。
Curr Biol. 2010 Jul 27;20(14):1283-9. doi: 10.1016/j.cub.2010.05.053. Epub 2010 Jun 17.
2
Investigations into the role of the Plasmodium falciparum SERCA (PfATP6) L263E mutation in artemisinin action and resistance.对恶性疟原虫 SERCA(PfATP6)L263E 突变在青蒿素作用和耐药性中的作用的研究。
Antimicrob Agents Chemother. 2010 Sep;54(9):3842-52. doi: 10.1128/AAC.00121-10. Epub 2010 Jun 21.
3
Geographic structuring of the Plasmodium falciparum sarco(endo)plasmic reticulum Ca2+ ATPase (PfSERCA) gene diversity.恶性疟原虫肌浆(内)质网 Ca2+-ATP 酶(PfSERCA)基因多样性的地理结构。
PLoS One. 2010 Feb 25;5(2):e9424. doi: 10.1371/journal.pone.0009424.
4
High prevalence of sulfadoxine/pyrimethamine resistance alleles in Plasmodium falciparum parasites from Bangladesh.孟加拉国恶性疟原虫中磺胺多辛/乙胺嘧啶抗性等位基因的高流行率。
Parasitol Int. 2010 Jun;59(2):178-82. doi: 10.1016/j.parint.2010.01.003. Epub 2010 Jan 22.
5
Artemisinin-based combination therapies: a vital tool in efforts to eliminate malaria.青蒿素类复方疗法:消除疟疾工作的重要工具。
Nat Rev Microbiol. 2009 Dec;7(12):864-74. doi: 10.1038/nrmicro2239. Epub 2009 Nov 2.
6
New PfATP6 mutations found in Plasmodium falciparum isolates from Vietnam.在越南恶性疟原虫分离株中发现新的PfATP6突变。
Antimicrob Agents Chemother. 2009 Oct;53(10):4570-1. doi: 10.1128/AAC.00684-09. Epub 2009 Aug 17.
7
Artemisinin resistance in Plasmodium falciparum malaria.恶性疟原虫疟疾中的青蒿素耐药性。
N Engl J Med. 2009 Jul 30;361(5):455-67. doi: 10.1056/NEJMoa0808859.
8
Molecular epidemiology of malaria in Cameroon. XXVIII. In vitro activity of dihydroartemisinin against clinical isolates of Plasmodium falciparum and sequence analysis of the P. falciparum ATPase 6 gene.喀麦隆疟疾的分子流行病学。二十八。双氢青蒿素对恶性疟原虫临床分离株的体外活性及恶性疟原虫ATP酶6基因的序列分析。
Am J Trop Med Hyg. 2009 Jul;81(1):13-8.
9
Arlequin (version 3.0): an integrated software package for population genetics data analysis.Arlequin(版本 3.0):一个用于群体遗传学数据分析的集成软件包。
Evol Bioinform Online. 2007 Feb 23;1:47-50.
10
Dynamics of malaria drug resistance patterns in the Amazon basin region following changes in Peruvian national treatment policy for uncomplicated malaria.秘鲁针对非重症疟疾的国家治疗政策发生变化后,亚马逊河流域地区疟疾耐药模式的动态变化
Antimicrob Agents Chemother. 2009 May;53(5):2042-51. doi: 10.1128/AAC.01677-08. Epub 2009 Mar 2.